Intellia TherapeuticsNTLA
NTLA
About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Employees: 598
0
Funds holding %
of 7,202 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
13% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 45
9% more call options, than puts
Call options by funds: $7.04M | Put options by funds: $6.43M
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
0.24% less ownership
Funds ownership: 97.45% [Q4 2024] → 97.22% (-0.24%) [Q1 2025]
0% less funds holding
Funds holding: 289 [Q4 2024] → 288 (-1) [Q1 2025]
6% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 96
38% less capital invested
Capital invested by funds: $1.16B [Q4 2024] → $716M (-$443M) [Q1 2025]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
3%
upside
Avg. target
$32
234%
upside
High target
$68
603%
upside
10 analyst ratings
7 positive
70%
3 neutral
30%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor | 210%upside $30 | Buy Reiterated | 20 May 2025 |
Wedbush David Nierengarten | 3%upside $10 | Neutral Reiterated | 19 May 2025 |
Guggenheim Debjit Chattopadhyay | 365%upside $45 | Buy Maintained | 12 May 2025 |
Citigroup David Lebowitz | 3%upside $10 | Neutral Maintained | 9 May 2025 |
Chardan Capital Geulah Livshits | 603%upside $68 | Buy Maintained | 9 May 2025 |
Financial journalist opinion
Based on 16 articles about NTLA published over the past 30 days
Positive
Seeking Alpha
11 hours ago
I Missed The Quantum Rally - I Won't Miss The Next One
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Neutral
GlobeNewsWire
2 days ago
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were shared in an oral presentation on Sunday, May 18 at the 2025 Peripheral Nerve Society (PNS) Annual Meeting in Edinburgh, United Kingdom. The Phase 3 MAGNITUDE-2 trial design of nex-z in ATTRv-PN was also exhibited in a poster presentation.
Positive
Zacks Investment Research
5 days ago
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Seeking Alpha
6 days ago
Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ET Company Participants Ed Dulac - CFO Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Hello, everyone. Thanks for joining the session with Intellia Therapeutics on day 1 of the 2025 Bank of America Healthcare Conference.
Neutral
Seeking Alpha
1 week ago
Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)
Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test results that were fine with medical experts and the FDA. The Street hated when NTLA dropped a lesser program and laid off some staff members. On 5/8/25, the Company reported further progress with two treatments that are now ensconced in Phase III of testing—a level only a third of new drugs reach.
Positive
Zacks Investment Research
1 week ago
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates.
Neutral
Seeking Alpha
1 week ago
Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President and Chief Executive Officer David Lebwohl - Chief Medical Officer Ed Dulac - Executive Vice President and Chief Financial Officer Birgit Schultes - Executive Vice President and Chief Scientific Officer Conference Call Participants Gena Wang - Barclays Kostas Biliouris - BMO Capital Markets Luca Issi - RBC Maury Raycroft - Jefferies Mitchell Kapoor - H. C. Wainwright Jay Olson - Oppenheimer Rick Bienkowski - Cantor Fitzgerald Yanan Zhu - Wells Fargo Troy Langford - TD Cowen Jake Roberge - William Blair Brian Cheng - JPMorgan William Pickering - Bernstein David Lebowitz - Citi Operator Good morning, and welcome to Intellia' First Quarter 2025 Financial Results Conference Call.
Negative
Zacks Investment Research
1 week ago
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an inducement grant to eight new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
Neutral
Seeking Alpha
2 weeks ago
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better positioned to navigate near-term challenges with a strong cash reserve and upcoming product launches, justifying an upgrade to 'Strong Buy.' NTLA, despite promising product candidates, faces higher risks and requires significant cost reductions to extend its cash runway, maintaining a "Buy" rating for high-risk investors.
Charts implemented using Lightweight Charts™